Roche firm on Genentech offer

Deal-watchers, take comfort. Roche says it's standing by its $43.7 billion offer to buy the rest of Genentech it doesn't own. Yes, there's been little activity on that deal lately, but Roche says it's still hungry for the buyout--and because Genentech shares have dropped below the $89 offer price, it might just decide to deal. Report

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.